Lupin Ltd Q4 FY2022 Concall Summary

Key Takeaways

• A reset quarter, with a deliberate cleanup: U.S. revenue fell below \$200M, driven by price erosion, the losartan recall, and Brovana LOE, while India grew just 5% in a seasonally weak quarter. Management framed the pain as a necessary clearing of legacy baggage.
• The margin bridge tells a story of one-offs: EBITDA margin declined sharply due to a ~₹127 crore sales drop, plus one-time hits from the losartan recall, Solosec litigation, and the absence of Q3's settlement income.
• A cost takeout of ₹500–1,000 crore is now the central promise: Management is targeting a material margin recovery by reducing idle time, airfreight, returns, write-offs, and low-margin SKUs, with ~₹450–500 crore of initiatives landing in FY23.
• The complex generics pipeline is the bull case, but it's being discounted: Management believes the market is ignoring the value of its inhalation, injectable, and biosimilar assets, with Spiriva, Pegfilgrastim, and Suprep as near-term catalysts.
• What to watch next quarter: Whether the Q1 U.S. softness is truly transient, the pace of the cost-reduction execution, and any FDA resolution at Somerset or Tarapur that could unlock the 160 pending approvals.

U.S. Business: Cleaning Up the Past

• Q4 revenue breakdown: The U.S. business fell below \$200M due to price decline, the losartan recall (inability to sell plus returns), Brovana loss of exclusivity, price reduction on Levothyroxine, and a weak acute therapy portfolio.
• Albuterol phasing: Winter months drive higher volume, which then tapers down, contributing to the sequential softness.
• Oral solids are the core problem: Double-digit pricing pressure continues on oral solids, compounded by mounting costs from idle time, inventories, and write-offs for flu season products. Inhalation and partnered products carry decent profitability.
• FTS penalties were an embarrassment: The company paid ~\$27 million in Failure to Supply penalties during FY22, a significant catch-up amount that management called "a bit of an embarrassment." The metric is now current and reflects only within-fiscal items.
• Product exits are now a formal strategy: For the first time, Lupin put together an SOP for planned exits, discontinuing certain negative-margin products. Ten products have already been dropped, with 3–4 more identified for FY23.
• Customer conversations have shifted: Management has told the three big U.S. buyers that Lupin does not want to be the largest volume supplier but rather a large value supplier, signaling a willingness to walk away from low-margin business.

Vinita Gupta: "We have told them that we don't want to be your largest volume supplier. We also want to be a large value supplier."

Margin Recovery & Cost Optimization

• Q4 margin headwinds were concentrated: The EBITDA margin decline was driven by ~₹127 crore from lower sales, plus one-time impacts: losartan recall costs (~\$11M), Solosec litigation loss (royalties and associated costs), and a swing from Q3 which had settlement incomes not repeated in Q4.
• Other expenses spiked to ₹970 crore: Beyond the recall and litigation costs, a significant shift of sales-force incentives from salary to other expense heads (~\$5M–\$6M) inflated the line item.
• The cost-optimization target is ₹500–1,000 crore: Initiatives include reducing idle time, shifting from airfreight back to ocean freight, cutting returns and write-offs, exiting low-margin SKUs, and optimizing network and R&D spend.
• Phasing of the benefit: ~₹450–500 crore of initiatives are expected to land in FY23, with the full impact flowing into FY24. The impact should start kicking in from Q2, alongside product launches like Suprep.
• Specialty burn eliminated: Management has completely taken the specialty burn off in the organization over the last year, and is working to externalize the NCE platform to remove its ~\$20 million annual burn, with savings expected in the second half.
• R&D spend to stay flat or decline: Current R&D run rate of ~₹350–375 crore (~8% of sales) is expected to be maintained or brought down "a tad" for the foreseeable future.

Ramesh Swaminathan: "I think the figure rest anywhere between INR500 crores to INR1,000 crores. So, it really depends on how much we can pull back on and how fast can we do that."

Complex Generics Pipeline: The Hidden Value

• Spiriva is on track: The FDA has communicated that chemistry, bioequivalence, PD, and labeling are all fine. A likely reinspection of the facility is needed before approval, and the device supplier in Germany is being inspected now. The target action date of August 2022 stands.
• Pegfilgrastim is a near-term biosimilar catalyst: Management hopes to get FDA-inspected and launch in the next 12 months. The Onpro presentation is about 10 months behind the PFS, and Lupin appears to be one of three in the first wave for Onpro, which would materially grow the franchise.
• Suprep launch expected soon: Final approval is pending, with validation batches underway now. The launch is expected next quarter from Somerset.
• Inhalation wave is building: Beyond Spiriva, the next 12 months include Dulera and Fostair. The next wave includes Qvar, Ellipta products, and Respimat products, all in development. Europe represents a material opportunity beyond the U.S.
• Biosimilars are a longer-term play: Lucentis clinical trial delays from Covid are resolved and the study is well underway, with a strong U.S. partnership position established. Eylea is a material opportunity after Lucentis, leveraging established ophthalmic specialty channel relationships. Etanercept U.S. entry is not expected until 2029.
• 160 pending approvals are the swing factor: First-to-files and launches from inhalation, injectables, and biosimilars are expected to be the big value drivers. First-to-files are mostly from Nagpur and Goa, which are protected sites.
• Management believes the pipeline is being discounted: The complex generics pipeline that Lupin has built is, in management's view, completely getting discounted by the market at this point.

Nilesh Gupta: "I think the complex generics pipeline that Lupin delivers, obviously, that's completely getting discounted at this point of time. And I think we have to reflect that in to results. But people who work closer they see it, right?"

India Business: Steady Underneath the Noise

• Q4 growth was tepid at 5%: This was an industry trend as Covid drugs came off and the additional Covid-counter market declined. Lupin was not positively impacted by Covid products, so it was not materially negatively impacted either.
• Underlying prescription growth was strong: The reported 5% YoY growth includes lumpy tender business. Underlying India prescription business grew 13.9% YoY.
• Therapy-area leadership is intact: Cardiac, diabetes, and respiratory are all growing faster than the market, with double-digit growth in respiratory and gynecology.
• Cidmus loss will drag FY23 growth: Organic growth this year will be sub-10% because Cidmus went out and certain exclusivities are running out. Normalized for in-licensed products, growth would be much higher. Management walked away because the valuation stretched beyond a 7–8 year payback period, which is their comfort limit.
• Three new divisions launched: New divisions for diabetes, CNS, and anti-infectives were launched in India, signaling continued investment in the domestic franchise.
• Acquisitions are on the radar: Management is keen on acquisitions in India and is chasing several assets, but will walk away if the payback exceeds 7–8 years. The 10–12% India growth target factors in acquisitions.

Vinita Gupta: "Once it goes out of the seven-year, eight-year payback period, we are not necessarily comfortable. So if it goes beyond that, usually, that's when we would walk away."

Compliance & Manufacturing: The Long Road Back

• Somerset remains the problem child: Leadership gaps in manufacturing and quality contributed to a poor inspection outcome. Both positions have been replaced, with the Head of Operations coming from Teva and the quality head filled externally. Management acknowledged that their track record does not speak well for Somerset.
• Tarapur inspection outcome pending: Observations were received and a response was sent at the end of the quarter. An update is expected soon, and management is hopeful of a satisfactory resolution.
• Goa is starting to deliver: Approvals are beginning to come through, with at least seven launches expected this year.
• Pithampur has stranded assets: Approximately 30 products are stuck. Some will not launch due to lost time value, but certain extended-release products remain good opportunities.
• Management churn compounded the problem: Significant turnover at the management and leadership level in both the U.S. and India created continuity issues. G&A functions in the U.S. (Finance, HR, IT) all turned over, though new capabilities brought in helped clean up past baggage like the FTS cleanup.
• Basic processes were antiquated: Supply chain processes were set 10–15 years ago. Integrated Business Planning (IBP) was implemented in the U.S. this past year and is now being rolled out ex-U.S. for developed markets.
• The aspiration is best-in-class, not the reality: Management is committed to getting across a 5-year compliance rut and knows they need to be best-in-class to be a strong generic company, but acknowledged they are not there yet.

Nilesh Gupta: "Again, our track record does not speak well for Somerset. But the team is extremely motivated to fix it, and this is kind of their opportunity now. They need to fix this now."

Strategic Direction & Capital Allocation

• The strategy is simplified: Core growth pillars are doubling down in India, delivering on the complex generics platform, and globalizing that platform. The oral solids business is not going to be the focus area, with only niche launches planned.
• Specialty and NCE are being de-emphasized: The specialty burn has been completely eliminated. The chemical entity platform does not give operating leverage or get valued in the current business, and efforts are underway to find the right path for it.
• R&D is shifting toward complex generics: More focus on inhalations, injectables, and biosimilars. The salience of NCE is expected to come down over time.
• CapEx and working capital are under scrutiny: A tight rein on CapEx outlays is continuing, and the team is working on optimizing working capital from the current ~145 days.
• Debt is a temporary situation: The company turned to a debt position because of one-time Glumetza settlement payments. Management expects it is a question of time to get back into a surplus situation, which will then be used for productive purposes including M&A.
• Anglo-French and Southern Cross acquisitions: The Anglo-French acquisition was consummated in the first week of April 2022, and the Southern Cross bolt-on in Australia was also announced and consumed.

Vinita Gupta: "I mean, we used to have specialty in here. As you've seen in the last year, we've pretty much taken the specialty burn off in the organization."

Guidance & Commitments

Key Metrics